

Alan Lyles

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11673044/publications.pdf>

Version: 2024-02-01

35
papers

1,482
citations

516710

16
h-index

477307

29
g-index

35
all docs

35
docs citations

35
times ranked

1542
citing authors

#	ARTICLE	IF	CITATIONS
1	Hospitalization and Death Associated With Potentially Inappropriate Medication Prescriptions Among Elderly Nursing Home Residents. <i>Archives of Internal Medicine</i> , 2005, 165, 68.	3.8	357
2	A Comparison of Risk Factors in Juvenile-Onset and Adult-Onset Recurrent Respiratory Papillomatosis. <i>Laryngoscope</i> , 1992, 102, 977-13.	2.0	179
3	Comparison of Prescribing Criteria to Evaluate the Appropriateness of Drug Treatment in Individuals Aged 65 and Older: A Systematic Review. <i>Journal of the American Geriatrics Society</i> , 2011, 59, 1521-1530.	2.6	162
4	Services to Families of Adults With Schizophrenia: From Treatment Recommendations to Dissemination. <i>Psychiatric Services</i> , 1999, 50, 233-238.	2.0	141
5	Potentially Inappropriate Medication Prescriptions among Elderly Nursing Home Residents: Their Scope and Associated Resident and Facility Characteristics. <i>Health Services Research</i> , 2004, 39, 1257-1276.	2.0	129
6	Direct Marketing of Pharmaceuticals to Consumers. <i>Annual Review of Public Health</i> , 2002, 23, 73-91.	17.4	88
7	AMCP Guidance for Submission of Clinical and Economic Evaluation Data to Support Formulary Listing in U.S. Health Plans and Pharmacy Benefits Management Organizations. <i>Journal of Managed Care Pharmacy</i> , 2001, 7, 272-282.	2.2	65
8	An In-home Advanced Robotic System to Manage Elderly Home-care Patients' Medications: A Pilot Safety and Usability Study. <i>Clinical Therapeutics</i> , 2017, 39, 1054-1061.	2.5	49
9	Managed care pharmacy, socioeconomic assessments and drug adoption decisions. <i>Social Science and Medicine</i> , 1997, 45, 511-521.	3.8	43
10	Use and Costs of Ambulatory Care Services Among Medicare Enrollees With Schizophrenia. <i>Psychiatric Services</i> , 2001, 52, 786-792.	2.0	40
11	Potentially Inappropriate Medication Use Among Finnish Non-Institutionalized People Aged ≥65 Years. <i>Drugs and Aging</i> , 2011, 28, 227-236.	2.7	39
12	Melatonin for sedative withdrawal in older patients with primary insomnia: a randomized double-blind placebo-controlled trial. <i>British Journal of Clinical Pharmacology</i> , 2014, 77, 975-985.	2.4	33
13	Effect of withdrawal from long-term use of temazepam, zopiclone or zolpidem as hypnotic agents on cognition in older adults. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 319-329.	1.9	32
14	CNS Medications as Predictors of Precipitous Cognitive Decline in the Cognitively Disabled Aged: A Longitudinal Population-Based Study. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2012, 2, 57-68.	1.3	26
15	Content validation of a tool for assessing risks for drug-related problems to be used by practical nurses caring for home-dwelling clients aged ≥65 years: a Delphi survey. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 991-1002.	1.9	22
16	Handgrip strength and balance in older adults following withdrawal from long-term use of temazepam, zopiclone or zolpidem as hypnotics. <i>BMC Geriatrics</i> , 2014, 14, 121.	2.7	20
17	Improved medication use in long-term care: building on the consultant pharmacist's drug regimen review. <i>American Journal of Managed Care</i> , 2002, 8, 318-26.	1.1	10
18	Cost And Quality Trends In Direct Contracting Arrangements. <i>Health Affairs</i> , 2002, 21, 89-102.	5.2	9

#	ARTICLE	IF	CITATIONS
19	Standards and certification to recognize pharmacoeconomics as a profession. <i>Clinical Therapeutics</i> , 2003, 25, 1004-1006.	2.5	5
20	Public-private partnerships at the national institutes of health: From discovery to commercialization. <i>Clinical Therapeutics</i> , 2003, 25, 2900-2902.	2.5	5
21	Decision-makers' use of pharmacoeconomics: what does the research tell us?. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2001, 1, 133-144.	1.4	4
22	The Prescription Drug User Fee Act: Active Postmarketing Drug Surveillance and Safety. <i>Clinical Therapeutics</i> , 2002, 24, 800-802.	2.5	4
23	Evidence- or opinion-based pharmaceutical policy?. <i>Clinical Therapeutics</i> , 2004, 26, 1922-1923.	2.5	4
24	Must an interest be a conflict?. <i>Clinical Therapeutics</i> , 2005, 27, 344-345.	2.5	4
25	The Relevance of International Studies to Informed Pharmacoeconomics and Health Policy Decisions. <i>Clinical Therapeutics</i> , 2010, 32, 106-107.	2.5	4
26	The prescribing continuum: Between prescription and over-the-counter drugs. <i>Clinical Therapeutics</i> , 2007, 29, 2244-2245.	2.5	3
27	Creating alternative incentives for pharmaceutical innovation. <i>Clinical Therapeutics</i> , 2006, 28, 126-128.	2.5	2
28	The Importance of Context to the Generalizability of International Research: The Other Health Care Reform. <i>Clinical Therapeutics</i> , 2010, 32, 2442-2443.	2.5	2
29	The symptom mitigation path of mobile community residents: Community pharmacy's role. <i>Health Policy</i> , 2009, 89, 14-25.	3.0	1
30	Health care reform: Is the process the outcome?. <i>Clinical Therapeutics</i> , 2009, 31, 2014-2017.	2.5	0
31	Muted Incentives, Omitted Variables, and Pharmacoeconomic Validity: Two Strikes and You're Out!. <i>Clinical Therapeutics</i> , 2011, 33, 60-61.	2.5	0
32	National Versus International Generalizations from Cost-Effectiveness Analyses. <i>Clinical Therapeutics</i> , 2011, 33, 1444-1445.	2.5	0
33	Pharmacy practice and health policy within the U.S., 2004, , 341-367.		0
34	Pharmaceutical Promotion in the United States., 2016, , 231-251.		0
35	Achieving healthy people 2010 immunization goals: proceedings of a national conference. Chapel Hill, North Carolina: October 12-13, 2001. Background. <i>Clinical Therapeutics</i> , 2003, 25 Suppl A, A2-8.	2.5	0